Black Cohosh Extract for Treatment of Moderate to Severe Menopausal Symptoms
BCOMS
Black Cohosh Extract for the Treatment of Moderate to Severe Menopausal Symptoms: a Randomized-placebo Controlled Trial
2 other identifiers
interventional
60
1 country
1
Brief Summary
Compare the treatment efficacy of black cohosh extract 80 mg daily and placebo for moderate to severe menopausal symptoms
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_3
Started Mar 2014
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2014
CompletedFirst Submitted
Initial submission to the registry
March 19, 2014
CompletedFirst Posted
Study publicly available on registry
March 21, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2016
CompletedSeptember 25, 2014
September 1, 2014
2 years
March 19, 2014
September 23, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The changes in Kupperman Index
Kupperman index questionnaire at baseline, 4, 8 and 12 weeks
baseline, week 4, week 8 and week 12
Secondary Outcomes (5)
A change in MENQOL
baseline and week 12
The changes in daily hot flushes frequency
baseline, week 4, week 8 and week 12
Global satisfaction
week 12
A change in liver function test
baseline and week 12
adverse events
week 4, week 8 and week 12
Study Arms (2)
Black cohosh extract
ACTIVE COMPARATORblack cohosh extract 80 mg daily
Placebo
PLACEBO COMPARATORMatching placebo
Interventions
Eligibility Criteria
You may qualify if:
- Age at least 40 years
- Peri or post menopause
- Moderate to severe menopausal symptoms (Kupperman index at least 20)
You may not qualify if:
- Use hormonal treatment or other treatments within 4 weeks
- Use atorvastatin azathioprine or cyclosporin within 4 weeks
- BMI at least 30 kg m2
- Allergic to drug or components
- Liver disease or abnormal liver function test
- Psychiatric disease
- Alcoholic or drug abuse
- Vegetarian
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Obstetrics and Gynecology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University
Dusit, Bangkok, 10300, Thailand
MeSH Terms
Interventions
Study Officials
- PRINCIPAL INVESTIGATOR
Patsama Vichinsartvichai, MD
Faculty of Medicine Vajira Hospital
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD.
Study Record Dates
First Submitted
March 19, 2014
First Posted
March 21, 2014
Study Start
March 1, 2014
Primary Completion
March 1, 2016
Study Completion
July 1, 2016
Last Updated
September 25, 2014
Record last verified: 2014-09